Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.
Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, Dean DC, Evers R. Chu XY, et al. Among authors: yabut j. J Pharmacol Exp Ther. 2007 May;321(2):673-83. doi: 10.1124/jpet.106.116517. Epub 2007 Feb 21. J Pharmacol Exp Ther. 2007. PMID: 17314201
Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A.
Prueksaritanont T, Tatosian DA, Chu X, Railkar R, Evers R, Chavez-Eng C, Lutz R, Zeng W, Yabut J, Chan GH, Cai X, Latham AH, Hehman J, Stypinski D, Brejda J, Zhou C, Thornton B, Bateman KP, Fraser I, Stoch SA. Prueksaritanont T, et al. Among authors: yabut j. Clin Pharmacol Ther. 2017 Apr;101(4):519-530. doi: 10.1002/cpt.525. Epub 2016 Dec 10. Clin Pharmacol Ther. 2017. PMID: 27943276 Clinical Trial.
Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.
Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, Stone JA, Ding Y, Witter R, Gibson C, Roupe K, Evers R, Wagner JA, Stoch A. Reitman ML, et al. Among authors: yabut j. Clin Pharmacol Ther. 2011 Feb;89(2):234-42. doi: 10.1038/clpt.2010.271. Epub 2010 Dec 29. Clin Pharmacol Ther. 2011. PMID: 21191377
Identification of potential pharmacological and toxicological targets differentiating structural analogs by a combination of transcriptional profiling and promoter analysis in LS-180 and Caco-2 adenocarcinoma cell lines.
Hartley DP, Dai X, Yabut J, Chu X, Cheng O, Zhang T, He YD, Roberts C, Ulrich R, Evers R, Evans DC. Hartley DP, et al. Among authors: yabut j. Pharmacogenet Genomics. 2006 Aug;16(8):579-99. doi: 10.1097/01.fpc.0000220561.59972.7a. Pharmacogenet Genomics. 2006. PMID: 16847427
Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model.
Dallas S, Salphati L, Gomez-Zepeda D, Wanek T, Chen L, Chu X, Kunta J, Mezler M, Menet MC, Chasseigneaux S, Declèves X, Langer O, Pierre E, DiLoreto K, Hoft C, Laplanche L, Pang J, Pereira T, Andonian C, Simic D, Rode A, Yabut J, Zhang X, Scheer N. Dallas S, et al. Among authors: yabut j. Mol Pharmacol. 2016 May;89(5):492-504. doi: 10.1124/mol.115.102079. Epub 2016 Feb 18. Mol Pharmacol. 2016. PMID: 26893303
37 results